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Background: Iron oxide nanoparticles (IONs) have been increasingly utilized in a wide
spectrum of biomedical applications. Surface coatings of IONs can bestow a number of
exceptional properties, including enhanced stability of IONs, increased loading of drugs or
their controlled release.
Methods: Using two-step sonochemical protocol, IONs were surface-coated with polyox-
yethylene stearate, polyvinylpyrrolidone or chitosan for a loading of two distinct topo II
poisons (doxorubicin and ellipticine). The cytotoxic behavior was tested in vitro against
breast cancer (MDA-MB-231) and healthy epithelial cells (HEK-293 and HBL-100). In
addition, biocompatibility studies (hemotoxicity, protein corona formation, binding of third
complement component) were performed.
Results: Notably, despite surface-coated IONs exhibited only negligible cytotoxicity, upon
tethering with topo II poisons, synergistic or additional enhancement of cytotoxicity was
found in MDA-MB-231 cells. Pronounced anti-migratory activity, DNA fragmentation,
decrease in expression of procaspase-3 and enhancement of p53 expression were further
identified upon exposure to surface-coated IONs with tethered doxorubicin and ellipticine.
Moreover, surface-coated IONs nanoformulations of topo II poisons exhibited exceptional
stability in human plasma with no protein corona and complement 3 binding, and only a mild
induction of hemolysis in human red blood cells.
Conclusion: The results imply a high potential of an efficient ultrasound-mediated surface
functionalization of IONs as delivery vehicles to improve therapeutic efficiency of topo II
poisons.
Keywords: doxorubicin, ellipticine, iron oxide, nanoparticles, release kinetics
Introduction
Over the past decades, nanomaterials have emerged as powerful tools in numerous
biomedical applications. In recent years, an increasing number of nanomedicines has
been already approved by the US Food and Drug Administration for human use and
others are undergoing clinical trials.1 Iron oxide nanoparticles (IONs) are believed to be
one of the promising candidates for applications including drug delivery, imaging and
many others.2–4 This is due to a high biocompatibility, ability to obey external magnetic
field (EMF), enabling a facile purification and controllable guiding of loaded drugs to
the diseased location and low synthesis costs.5–7
As drug delivery systems, IONs usually comprise three major components: i) a
magnetic core composed of iron oxide; ii) a surface layer exhibiting appropriate
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stabilization and affinity to the desired payload; and iii)
payload, which is usually a bioactive molecule.8 In a large
number of reports, the loading of drugs is achieved
through covalent binding, limiting the generality of strat-
egy, particularly for small molecule-based drugs that are
hard to conjugate or are losing their cytotoxicity when
conjugated.9,10 Therefore, efforts have been made to tailor
surface layers (or coatings) that can adsorb therapeutics,
enable for a controlled release kinetics profiles and also
reduce the non-specific or unpleasant interactions with
host.11,12 The coating agents also protect IONs from che-
mical reactions and enhance their stability by preventing
hydrophobic–hydrophobic interactions leading to aggrega-
tion of IONs.13 In this way, a number of reports have
investigated exploitation of biocompatible, non-antigenic
polymers or surfactants, including polyethylene glycol,
poloxamers, starch or polyethylene imine14–17 to stabilize
and functionalize surface of IONs. However, due to
diverse physicochemical nature of both, surface coatings
and drugs, the IONs surface coating-drug pairs need to be
optimized in detail.
Topoisomerase II (topo II) poisons stimulate DNA
double-strand breakage through interference with the
cleavage/ligation reaction of DNA topo II.18 Such inhi-
bition results in the genome instability and consequent
cell death.19 Group of topo II poisons comprises several
clinically important and highly active anti-cancer agents
including doxorubicin (Dox), etoposide or mitoxantrone.
Noteworthy, there are important negative consequences
of using these agents, such as development of secondary
malignancies, induction of cardiotoxicity and many
others.20,21 These are triggered by a low tumor tissue
selectivity and accumulation in rapidly proliferating
non-malignant cells. Hence, an important goal of present
and future work is to maximize therapeutic efficiency of
topo II poisons while minimizing their adverse effects.
Indeed, among the most potent solution belongs nano-
medicines-mediated delivery and sustained release of
topo II poisons in targeted diseased tissue.
Therefore, the present study describes a facile pro-
duction of surface-coated IONs capable to bind and
release topo II poisons in slightly acidic (endosomal
or hypoxic) microenvironment. Surface coating was
optimized for two selected topo II poisons: (i) Dox
hydrochloride, which is a hydrophilic compound and
a prototype of anthracycline antibiotics22 and (ii) ellip-
ticine (Elli), which is a highly toxic, poorly water-
soluble alkaloid with a significant anti-cancer activity,
but also a pronounced non-target toxicity.23 Due to a
diverse nature of these two compounds, three types of
IONs-surface coatings [polyoxyethylene stearate
(POES), polyvinylpyrrolidone (PVP) and chitosan
(Chit)] were evaluated in terms of testing the ultra-
sound-mediated tethering to increase loading efficiency
(LE) of topo II poisons, their release kinetics, cytotoxi-
city and biocompatibility in vitro.
Materials and methods
Chemicals
Listed chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA) in ACS purity, unless noted
otherwise.
Synthesis of bare ions
IONs were prepared through the oxidation of a Fe(OH)2 gel
in the presence of KNO3 at 90°C.
24 More precisely, 12.5 mL
of 1 M KOH solution and 25.0 mL of 2 M KNO3 were
added to 81.3 mL of degassed Milli-Q water in screwable
flask. Meanwhile, 1 M solution of Fe2SO4·7H2O in
degassed water was prepared. Subsequently, 6.75 mL of
FeSO4·7H2O solution was mixed with the KOH and
KNO3 solution described above. The mixture, which turned
green at that point, was purged with N2 for 1 min. Flask was
tightly closed with a screw cap and placed in a water bath
that had been preheated to 90°C. The flask was left in the
bath for 2 hrs. After that time, the flask was taken out of the
bath and cooled down at ambient temperature. The resulting
black precipitate was washed several times with water. Nd-
Fe-B permanent magnet was used to speed up sedimenta-
tion of the precipitate and to facilitate the washing process.
Surface coating of bare IONs
For surface coating, 1.0 mL of IONs (5 mg/mL) was
mixed with 1.0 mL of Milli-Q water containing POES,
PVP or Chit in concentrations 2.5–10 mg/mL. The solu-
tion was dispersed with ultrasonication for 20 mins with
the power and the frequency of 80/320 W and 35 kHz,
respectively (Bandelin Sonorex Super RK 31 H, Bandelin
Electronic GmbH, Berlin, Germany). To remove unbound
molecules, the solution was washed five-times with
Milli-Q water using Nd-Fe-B permanent magnet. To quan-
tify the amount of the organic surface coatings, solid
samples were dried, weighted to 1.0–3.0 mg and placed
in tin cups. In a typical run, two bypasses (empty-folded
tin cups) and sample (done in triplicate) were placed in the
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Flash 2000 Element Analyzer (Thermo Fisher Scientific,
Waltham, MA, USA) and combusted at 950°C for 720 s
using 2,5-bis(5-tert-butyl-benzoxazol-2-yl)thiopene as the
standard and K factor as the calibration method.
Percentage of the organic matter was recalculated as the
ratio between the total sample weight and the sum of
average amounts of elements (CHNS/O) determined by
the analyzer.
Tethering of topo II poisons
Tethering of topo II poisons (Elli and Dox in form of Dox
hydrochloride) onto the surface of surface-coated IONs
was performed by mixing 1 mL of surface-coated IONs
(1 mg/mL) with 1 mL of Dox or Elli (2 mg/mL), followed
by ultrasonication with power and frequency of 80/320 W
and 35 kHz, respectively (Bandelin Sonorex Super RK 31
H, Bandelin Electronic GmbH) or incubation in
ThermoMixer®C (Eppendorf, Hamburg, Germany) for 20
mins. For both protocols, dependence of temperature on
tethering was evaluated at 10°C, 20°C and 40°C. Finally,
IONs were washed five times with PBS to get rid of the
loosely bound Dox or Elli. Finally, drug-loaded IONs were
dispersed into 2 mL of Milli-Q water. After washing,
tethering was validated and the LE was quantified by
fluorescence spectroscopy through intrinsic fluorescence
of Dox (λexc 480 nm, λem 560 nm) or Elli (λexc 305 nm,
λem 470 nm) using plate reader Infinite 200 PRO (Tecan,
Maennedorf, Switzerland). The LE was calculated as
follows25:
LE %ð Þ¼ initial Dox=Ellið Þ supernatant freeDox=Ellið Þ½ =




The morphology of IONs was investigated using scanning
electron microscope (SEM) MIRA 2 (Tescan, Brno, Czech
Republic). Colloidal stability of surface-coated IONs was
studied upon dispersion in Ringer´s solution (6.5 g sodium
chloride, 0.42 g potassium chloride, 0.25 g calcium chloride
and 0.2 g of sodium bicarbonate dissolved in 1 L of water, pH
7.4), which is an isotonic solution mimicking plasma environ-
ment. Hydrodynamic diameter (dhy), ζ-potential and polydis-
persity index (PDI) were evaluated using Doppler
microelectrophoresis and quasielastic dynamic light scattering
on Zetasizer Nano ZS90 (Malvern Instruments, Malvern,
UK). The refractive index of dispersive environment was
1.333 for all tested samples. For each ζ-potential measure-
ment, number of runs varied between 20 and 40, and calcula-
tions considered the diminution of particle concentration based
on the Smoluchowski model, with an F(ka) of 1.5. Analyses
were performed in Ringer's solution (100-fold diluted with
Milli-Q water) or fully supplemented culture medium (30
mins incubation in RPMI-1640 with 10% FBS). For mass--
normalization in experiments comparing the effect of surface-
coated IONs with and without tethered Dox and Elli, the total
Fe content in IONs was quantified using atomic absorption
spectrometer (AAS) Agilent 280ZAA with Zeeman back-
ground correction at primary wavelength 248.3 nm (Agilent
Technologies, Santa Clara, CA, USA).
In vitro release kinetics of topo II poisons
from surface-coated ions
1 mL of surface-coated or bare IONs with tethered Dox and
Elli (both 200 µg/mL) was dispersed in solutions mimicking
physiological conditions. These were: i) Ringer´s solution
mimicking plasma (composition described above), ii) buffer
mimicking neutral intracellular fluid (0.212 g magnesium
chloride hexahydrate, 6.415 g sodium chloride, 0.318 g cal-
cium chloride tetrahydrate, 0.179 g sodium sulfate decahy-
drate, 0.148 g disodium phosphate, 2.703 g sodium
bicarbonate, 0.18 g sodium tartrate dihydrate, 0.144 g triso-
dium citrate dihydrate, 0.175 g sodium lactate, 0.118 g glycine
and 0.172 g sodium pyruvate in 1 L of water, pH 6.9), and iii)
buffer mimicking acidic environment of endosomes 0.142 g
disodium phosphate, 6.650 g sodium chloride, 0.071 g sodium
sulfate, 0.029 g calcium chloride dihydrate, 0.45 g glycine and
4.1 g potassium hydrogen phthalate in 1 L of water, pH 5.0).
The temperature was maintained at 37°C. At fixed time inter-
vals, IONs were immobilized by a permanent magnet and 50
μL of mediumwas withdrawn and subsequently replaced with
freshmedium tomaintain the sink conditions.25 The amount of
released Dox and Elli was determined using plate reader
Infinite 200 PRO (Tecan) at λexc 480 nm, λem 560 nm for
Dox and λexc 305 nm, λem 470 nm for Elli. The cumulative
release was calculated as follows:
Cumulative release %ð Þ¼ Dox=Elli in the mediumð Þ=
Initial Dox=Ellið Þ  100
(2)
Cell lines and culture conditions
Cell lines used in this study were: i) the HBL-100 epithe-
lial human cell line established from milk of apparently
healthy woman, ii) the HEK-293 established from human
Dovepress Michalkova et al
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embryonic kidney, and iii) the MDA-MB-231 established
from a pleural effusion of a 51-year-old woman with
triple-negative metastatic breast cancer. Cell lines were
purchased from American Type Culture Collection
(Manassas, VA, USA). HBL-100 and HEK-293 cell lines
were cultured in DMEM and MDA-MB-231 cells were
cultured in Roswell Park Memorial Institute (RPMI-1640).
Media were supplemented with 10% FBS and penicillin
(100 U/mL) and streptomycin (0.1 mg/mL). The cells were
maintained at 37°C in a humidified incubator Galaxy® 170
R (Eppendorf, Hamburg, Germany).
Cytotoxicity screenings and analysis of
IONs-topo II poisons synergism
Treatments were initiated after the cells reached ~60–80%
confluence. Cells were harvested by trypsinization, washed
four times with phosphate-buffered saline (PBS, pH 7.4)
and counted using Countess II FL Automated Cell Counter
(Thermo Fisher Scientific). Viability was assayed using
XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetra-
zolium-5-carboxanilide) assay. Briefly, the suspension of
5,000 cells in 100 µL DMEM or RPMI-1640 was added
to each well of microtiter plates, followed by incubation for
24 rs at 37°C with 5% CO2 to ensure cell growth. Then, 50
µL of media containing annotated treatment agent was
added to the cells. Upon 24 hrs incubation, 25 µL of XTT/
phenazine methosulfate mixture was added directly to each
well followed by incubation (2 hrs at 37°C). Absorbance of
the samples was determined at 450 nm (Infinite 200 PRO,
Tecan). Level of IONs-topo II poisons synergism was ana-
lyzed using the Chou-Talalay analysis26 by plotting isobo-
lograms and determining combination indices (CI) using
CompuSyn software (www.combosyn.com).
Quantitation of total intracellular iron
The total content of intracellular iron from IONs was
determined using a 280ZAA (AAS) (Agilent) with elec-
tro-thermal atomization. Iron was quantified at primary
wavelength 248.3 nm (spectral bandwidth 0.5 nm).
Zeeman background correction was used with a field
strength of 0.8 T. Prior to analyses, iron was extracted
from 10 μg of cell pellet (cells were treated with IONs
normalized to 5 μg/mL of tethered topo II poisons for 6
hrs) using 200 μL of Suprapur® HNO3 and 300 μL of
MilliQ water (140°C, 30 mins using Multiwave 3000,
Anton Paar, Graz, Austria). Before extraction, cells were
washed with 10 μM ethylenediaminetetraacetic acid
(EDTA).
Investigation of internalization of topo II
poisons-tethered IONs
Cells (~3×103) were dispersed onto each object chamber
slides (Thermo Fisher Scientific). Following incubation for
24 hrs at 37°C, the chambers were washed with PBS and
the cells were incubated with Dox@IONs-POES and
Elli@IONs-PVP (5 μg/mL of each topo II poison) up to
6 hrs. After washing with PBS (3 times), the cells fixed
with 4% paraformaldehyde solution for 20 mins and
washed with PBS containing 0.1% Triton X-100 for 3
times. The cell nuclei were counterstained with Hoechst
33258. The fluorescence images were obtained using con-
focal laser scanning microscope (CLSM) LSM 880 (Carl
Zeiss, Jena, Germany).
Wound-healing assay (Scratch test)
The cells were seeded into 6-well plate and incubated to
reach the ~100% confluence. Then, a pin was used to
create an artificial wound in the confluent monolayer.
The wells were washed with PBS to remove cells and to
form a cell-free zone. Then, cells were re-suspended in a
fresh medium containing either Dox@IONs-POES or
Elli@IONs-PVP (5 μg/mL of each topo II poison). After
24 hrs incubation, the pictures of cells were taken and
compared with pictures obtained at start-point (0 hr),
using TScratch software (CSElab, Zurich, Switzerland).
Single-cell gel electrophoresis (SCGE)
The cells were seeded at a density of ~106 cells/well in six-
well dishes and treated with Dox@IONs-POES or
Elli@IONs-PVP (5 μg/mL of each topo II poison) for 6
hrs. As a positive control, 60 µM H2O2 was employed.
After harvesting by trypsinization and centrifugation, about
15 μL of the cell suspension was mixed with 75 μL of 0.5%
low melting point agarose (CLP, San Diego, CA, USA) and
layered on one end of a frosted plain glass slide. Then, it was
covered with a layer of the low melting agarose (100 μL).
After solidification of the gel, the slides were immersed in a
lysing solution (2.5 M NaCl, 100 mM Na2EDTA, 10 mM
Tris, pH 10) containing 1% Triton X-100 and 10% dimethyl
sulfoxide overnight incubation at 4°C. A cold alkaline elec-
trophoresis buffer was poured into the chamber and incu-
bated for 20 mins at 4°C. The electrophoresis was carried at
4°C for 30 mins, at (1.25 V/cm) and 300mA. The slides were
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neutralized (0.4 M Tris, pH 7.5) and then stained with ethi-
dium bromide (2 µg/mL). The cells were analyzed under
EVOS FL Auto Cell Imaging System (Thermo Fisher
Scientific) and classified according to the shape of the fluor-
escence of the comet tail [0 (no visible tail) to 4 (significant
DNA in tail)].
Hemocompatibility
Hemocompatibility of Dox@IONs-POES or Elli@IONs-PVP
was assayed using red blood cells (RBCs, Zen-Bio, Durham,
NC, USA). After thawing, RBCs were washed with 150 mM
NaCl solution three-to-five times. Then, annotated concentra-
tions of Dox@IONs-POES or Elli@IONs-PVP diluted in PBS
were mixed with RBCs and incubated for 1 hr at 37°C. The
degree of hemolysis was determined by quantifying the absor-
bance of the supernatant at 540 nm, after centrifugation and
calculated according to following equation:
%hemolysis ¼ AtAcð Þ=A100%Ac½ Þ  100 (3)
where At is the absorbance of the supernatant from sam-
ples incubated with IONs; Ac is the absorbance of the
supernatant from negative control (PBS, pH 7.4); A100%
is the absorbance of the supernatant of positive control
(0.1% Triton X-100), which causes complete lysis of
RBCs.
Analysis of the formation of protein
coronas
IONs-containing solutions (normalized to iron content by
AAS) were incubated in human serum (from male AB
clotted whole blood) at 1:1 volume ratio (v/v) in order to
mimic the protein concentration in vivo (50% plasma in
blood). The incubation was done for 1 hr at 37°C under
continuous agitation (450 rpm). The protein coronas were
recovered after 10 mins centrifugation at 15,000×g, and
washed five times with cold PBS to remove the unbound
proteins. Finally, the proteins were eluted by adding SDS,
separated by 12% one-dimensional SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and stained by Coomassie bril-
liant blue. Gels were visualized using Azure c600 (Azure
Biosystems, Dublin, CA, USA). Plasma proteins were also
quantified by densitometric analysis with the AzureSpot soft-
ware (Azure Biosystems).
Western blotting
Upon treatment with Dox@IONs-POES or Elli@IONs-PVP
(5 μg/mL of each topo II poison, 6 hrs), total cellular proteins
from MDA-MB-231 cells were extracted with 100 µL of
RIPA buffer containing protease inhibitor cocktail. After
electrophoresis, the proteins were electrotransferred onto
the Immuno-Blot® PVDF membrane (Bio-Rad, Hercules,
CA, USA) and blocked with 10% (w/v) skim milk powder
for 1 hr at 37°C. Membranes were incubated with primary
mouse anti-GAPDH (1:700), mouse anti-β-actin (1:700),
mouse anti-Bcl-2 (1:200), mouse anti-p53 (1:250), mouse
anti-MT1-1/2 (1:200) and mouse anti-MT-3 (1:200). After
washing, membranes were incubated with relevant horserad-
ish peroxidase-labeled secondary antibody (p0260, 1:5,000,
Dako, Glostrup, Denmark) for 1 hr at 20°C. Signals were
developed using Clarity Western ECL Blotting Substrate
(Bio-Rad) and blots were visualized using Azure c600 ima-
ger (Azure Biosystems).
Evaluation of binding of third complement
component (C3)
Upon incubation in human serum from male AB clotted
whole blood at 1:1 ratio (v/v) for 1 hr at 37°C, surface-
coated IONs bound proteins were electrophoresed and
electrotransferred onto the Immobilion®-FL membrane
(EMD Millipore, Burlington, MA, USA). Blocking and
immunoblotting of C3 was performed as described
above using the C3 monoclonal antibody, LF-MA0132,
Thermo Fisher Scientific, dilution 1:1,000.
Descriptive statistics
For the statistical evaluation of the results, the mean
was taken as the measurement of the main tendency,
while positive and negative error was taken as the
dispersion measurement. Differences between groups
were analyzed using paired t-test and ANOVA. For
analyses, Software Statistica 12 (StatSoft, Tulsa, OK,
USA) was employed.
Results
Preparation and characterization of bare
and surface-coated ions
Bare IONs were synthesized through the oxidation of Fe
(OH)2 gel in the presence of KNO3 at 90°C according to
Sugimoto and Matijevic.24 To stabilize bare IONs and to
functionalize their surface, three distinct types of organic
layers (PVP, POES or Chit) were deposited through ultra-
sound-mediated coating process.27 This was followed by
an extensive washing and optimization of a tethering of
two selected topo II poisons, Dox and Elli (synthesis
procedure is schematized in Figure 1A). The morphology
Dovepress Michalkova et al
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and particle size of bare and surface-coated IONs were
observed under SEM. As shown in Figure 1B, bare IONs
were spherical-to-polyhedral with the core having dia-
meter ~420 nm. Noteworthy, ultrasound-mediated deposi-
tion of organic coatings caused apparent slight collisions
in IONs surface, which is in line with the study by Sodipo
et al27. Resulting surface organic matter formed 0.1%
(POES), 0.2% (PVP) or 0.9% (Chit) of total IONs weight
(Figure 1C). This confirms a successful coating procedure
and indicates a thin surface coating of IONs. Moreover,
Figure 1D illustrates that organic surface coatings
enhanced the colloidal stability of IONs dispersed in
Ringer´s solution and contrary to bare IONs, sedimenta-
tion started after approx. 12 hrs incubation. To further
predict the colloidal stability of IONs in vivo, their dhy
in the Ringer´s solution (buffer mimicking plasma envir-
onment) was monitored over time. As shown in Figure 1E,
the highest increase in particle dhy was found for bare
IONs. For surface-coated IONs, agglomeration occurred
slowly and in much lesser extent. This phenomenon was
further confirmed by quantifying PDI (Figure 1F), indicat-
ing the lowest stability for bare IONs. Overall, the results
confirmed a successful surface coating of IONs with ben-
eficial properties toward their stability in physiological
environment.
Surface tethering of topo II poisons
After surface coating of IONs, tethering of Dox and Elli was
optimized in terms of tethering time, surface-coating agents’
concentrations, incubation temperature and involvement of
Figure 1 Surface coating of IONs with biocompatible surfactant (POES) or polymers (PVP and Chit). (A) Schematic representation of surface coating of bare IONs with
PVP, POES and Chit with a consequent tethering of cytotoxic substances Dox and Elli using incubation or ultrasonication, respectively. (B) SEM micrographs of morphology
of bare IONs and their morphology after surface coatings. The scale bars, 400 nm (left) or 5 µm (right). (C) Content of organic matter in surface-coated formulations
analyzed using CHNS/O analyzer. The values are expressed as the mean of three independent replicates (n=3). Vertical bars indicate standard error. (D)
Photodocumentation of a colloidal stability of bare and surface-coated IONs. Time-evolution of (E) dhy and (F) PDI, both analyzed in Ringer's solution. The values are
expressed as the mean of six independent replicates (n=6). The vertical bars + and − errors.
Abbreviations: IONs, iron oxide nanoparticles; POES, polyoxyethylene stearate; PVP, polyvinylpyrrolidone; Chit, chitosan; SEM, scanning electron microscopy; dhy,
hydrodynamic diameter; PDI, polydispersity index.
Michalkova et al Dovepress
submit your manuscript | www.dovepress.com
DovePress





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ultrasonication vs simple incubation. Interestingly, in some
experiments, LE dependence on temperature exhibited a
non-linear behavior, which is most likely due to a propensity
of surface coatings to swell or shrink, directly affecting a
portion of interaction sites for drug binding.28 However, to
fully understand this phenomenon on a surface of IONs,
further analyses might be done. Calculated LEs are shown
in Figure 2A. It can be generalized that ultrasonication
resulted in better LEs for both topo II poisons. On the other
hand, both topo II poisons display distinct loading affinity to
different surface coatings. The highest tethering of Dox was
achieved using IONs-POES (LE ~70%, approx. 1.4 mg Dox/
mg of IONs-POES), while Elli was best tethered to IONs-
PVP (LE ~60%, approx. 1.2 mg Elli/mg of IONs-PVP).
Finally, IONs-Chit bound only 20% of Dox and 30% of
Elli. It is also worth to note, that equal tests were carried
out with bare IONs that bound approx. 45% of Elli and only
20% of Dox. SEM micrographs in Figure 2B illustrate that
the second application of ultrasound caused larger surface
collisions and deformations resulting in the formation of
smaller particles on IONs surface. This resulted in a slight
increase in PDI and broadening of IONs dhy distribution
(Figure 2C). Additionally, to predict a biological behavior
of IONs, we performed incubation of bare and various sur-
face-coated IONs with or without tethered topo II poisons in
fully supplemented culture medium. Mean ζ-potential values
are summarized in Table 1. It was found that bare IONs
exhibit only low medium stability, supporting the need for a
proper surface coating. Noteworthy, in case of IONs with
tethered topo II poisons, incubation in culture medium
Figure 2 Optimization of loading of Dox and Elli onto surface-coated IONs. (A) Different amounts of surface-coating agents were tested for their LE with constant
amounts for Dox and Elli (2 mg/mL). (B) SEM micrographs showing selected surface-coated IONs after 20 mins ultrasonication-mediated tethering of Dox or Elli. Scale bars,
5 µm (top), 400 nm (bottom). (C) Distribution of dhy of Dox/Elli-loaded surface-modified IONs with the highest LEs. Inserted are PDI and ζ-potential values of IONs
dispersed in Ringer´s solution. (D) Photographs of bare IONs and selected topo II poisons-tethered surface-coated IONs after the application of an EMF (Nd-Fe-B
permanent magnet, 30 mins).
Abbreviations: IONs, iron oxide nanoparticles; LE, loading efficiency; Dox, doxorubicin; Elli, ellipticine; SEM, scanning electron microscopy; PDI, polydispersity index; EMF,
external magnetic field.
Dovepress Michalkova et al
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resulted in a slight alteration of ζ-potentials (for comparison,
see ζ-potential values recorded in PBS inserted in Figure 2C).
Lastly, it must be noted that upon tethering, IONs retained
their ability to respond to EMF and after 30 mins all IONs are
immobilized on EMF without obvious impurities in a solu-
tion (Figure 2D).
In vitro release of topo II poisons
The successful liberation of a drug in the target site is
fundamental for each cancer-targeted delivery system.
Thus, we analyzed the release kinetics of Dox and Elli in
three environments, mimicking physiologically relevant
environments. Cumulative release profiles revealed pH-
responsive behavior, particularly for Elli@IONs-PVP and
Dox@IONs-POES (Figure 3). Both formulations exhibited
sustained release in acidic (endosomal, pH 5.0) buffer
(85% release of Elli and 55% release of Dox after 24
hrs), which is significantly higher (P<0.01) compared to
release of Dox or Elli in plasma or neutral environments.
Interestingly, bare IONs, IONs-Chit and IONs-POES were
capable of relatively fast burst release of Dox or Elli in all
three tested buffers, indicating weak interactions between
drugs and nanomaterials.
Cytotoxic activity
We further performed a set of in vitro analyses to evaluate
the cytotoxic effects of surface-coated IONs with tethered
topo II poisons. Cytotoxicity was assayed on three differ-
ent types of cells, malignant MDA-MB-231 and non-
malignant HBL-100 and HEK-293. 24hIC50 values are
summarized in Table 2.
Overall, MDA-MB-231 cells were more susceptible
to Dox and Elli, which corresponds to their faster
proliferation rate. In opposite, surface-coated IONs
without tethered drugs caused only negligible cytotoxic
effects in extremely high concentrations. The highest
cytotoxicity found for IONs-Chit could be attributed to
their positive surface charge (ζ-potential 31.1±0.4 mV)
causing cytotoxic effects by interacting with negatively
charged membranes.29 Interestingly, relatively low
cytotoxicity was found for Dox@IONs-Chit. We antici-
pate that this is due to a strong binding of Dox onto the
IONs-Chit surface as demonstrated in Figure 3. Among
the most potent nanoformulations belonged
Dox@IONs-POES and Elli@IONs-PVP, which also
exhibited very good LEs and release kinetics profiles.
Therefore, these two variants were employed for
further analyses. Since in some treatments, surface-
coated IONs nanoformulations displayed lower
24hIC50 values than free drugs, we evaluated possible
synergistic effects using the Chou-Talalay method.26
The determined CIs demonstrate that IONs-POES pos-
sesses synergistic effects to Dox in MDA-MB-231 cells
(CI 0.692). In other surface-coated IONs formulations,
the effects were more additive (CI=1.0, Elli@IONs-
PVP in MDA-MB-231) or slightly antagonistic
(CI˃1.0, both nanoformulations in all tested non-malig-
nant cells). This phenomenon was corroborated by the
normalized isobolograms shown in Figure 4A. As a
follow-up of these findings, analysis of internalization
was performed through quantitation of total intracellu-
lar iron in cells treated with bare IONs (both, unsoni-
cated and sonicated), Dox@IONs-POES and
Elli@IONs-PVP. Interestingly, in contrast to non-
malignant HEK-293 and HBL-100 cells, MDA-MB-
231 cells displayed the highest capability to internalize
IONs irrespective on the surface functionalization
(Figure 4B). In addition, we found that all cell lines
accumulate a higher content of iron upon incubation
with bare-sonicated IONs (compared to their unsoni-
cated counterparts). This highlights the fact that smal-
ler particles formed during sonochemical steps
markedly contribute to the amount of total intracellular
iron. CLSM analyses revealed that malignant MDA-
MB-231 cells display the fastest uptake capability for
both, Dox@IONs-POES and Elli@IONs-PVP, and after
6 hrs upon treatment, topo II poisons are present in
nuclei (Figure 4C).
Table 1 Mean ζ-potential values of bare and surface-modified
IONs upon incubation in fully supplemented culture medium
(RPMI-1640 with 10% of FBS)








Notes: Prior analysis, samples were incubated in fully supplemented culture med-
ium (RPMI-1640 with 10% FBS). ζ-potential values are means of three independent
experiments (n=3).
Abbreviations: IONs, iron oxide nanoparticles; PVP, polyvinylpyrrolidone; POES,
polyoxyethylene stearate; Chit, chitosan; Dox, doxorubicin; Elli, ellipticine.
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Anti-migratory activity and mechanism of
action
Cell migration is among the major biological characteristics
of malignant cells. Therefore, we examined the effect of
Dox@IONs-POES and Elli@IONs-PVP on a migration of
all three tested cell types (representative micrographs are
shown in Figure 5A). Interestingly, in agreement with cyto-
toxic and internalization analyses, the highest anti-
migratory activity was found in MDA-MB-231 (Figure
5B). Contrary to that, the lowest inhibitory effect was
found for non-malignant HBL-100 cells. Since topo II poi-
sons induce DNA cleavage,19 we further carried out SCGE
to quantify the DNA fragmentation due to Dox@IONs-
POES and Elli@IONs-PVP exposure (Figure 5C). As
shown in Figure 5D, both nanoformulations caused exten-
sive DNA fragmentation (comet grades 3 and 4) in MDA-
Figure 3 In vitro cumulative release kinetic profiles of Dox and Elli from bare and surface-coated IONs determined in various physiological pH conditions (intracellular, pH
6.9, endosomal, pH 5.0 and plasma, pH 7.4). The values are expressed as the mean of six independent replicates (n=6). Vertical bars indicate + and −errors. The p-values
were calculated for each time-point and denoted if found to be significantly different, *P<0.05, **P<0.01.
Abbreviations: Dox, doxorubicin; Elli, ellipticine; IONs, iron oxide nanoparticles.
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MB-231 cells, in which almost complete fragmentation was
found. In contrast, a higher number of lower grade comets
was observed in HEK-293 and HBL-100 cells. This phe-
nomenon corroborates a partial selectivity of surface-coated
IONs nanoformulations of topo II poisons to malignant
MDA-MB-231 cells. Thus, whole-cell lysates of these
cells were investigated to identify possible effects of IONs
on crucial regulatory proteins. Figure 5E illustrates that
both nanoformulations are capable to decrease the amount
of executioner procaspase-3. Despite both, Dox and Elli are
capable to induce oxidative stress and IONs presence could
plausibly lead to a deregulation of metal homeostasis,30–32
no effect on the expression of MT-1/2 or MT-3 was found.
Moreover, similar to free Dox, Dox@IONs-POES and
Elli@IONs-PVP caused slight enhancement of p53
expression.
In vitro biocompatibility
In general, for use in vivo settings, nanomaterials should not
interact with blood elements. To delineate this phenomenon,
we investigated the possible hemolytic effects of Dox and
Elli tethered to surface-coated IONs. Figure 6A shows that
both nanoformulations induced a dose-dependent hemolytic
response of human RBCs. The highest applied concentra-
tions caused 42% (Dox@IONs-POES) or 27%
(Elli@IONs-PVP), respectively. It is worth noting that
lower concentrations induced acceptable rate of hemolysis
(~5%).33 Moreover, hemolysis induced by IONs-PVP and
IONs-POES without tethered topo II poisons was compar-
able to that of PBS. Another pivotal aspect of hemocompat-
ibility is nanomaterial–blood proteins interaction. Hence, we
further investigated rate of adsorption of plasma proteins
(referred to as protein corona) on the IONs surface. Figure
6B shows that despite bare IONs form extensive protein
corona, surface coating with POES and PVP is capable to
markedly inhibit this phenomenon. Interestingly, Elli-IONs-
PVP formed corona pattern similar to bare IONs. This can be
explained by a disruption of PVP coating due to a second
sonochemical modification step required for Elli tethering.
Finally, we evaluated the binding of C3 that can trigger a
nanoparticles engulfment by leukocytes and macrophages
through complement receptors and consequent recruitment
of inflammatory cells and anaphylaxis.34,35 Figure 6C shows
that no α chain fragment of C3b was bound on the IONs
surface, which is in line with no or only negligible formation
of protein corona, considered as a crucial prerequisite for
opsonization of nanomaterials.36
Discussion
IONs have attracted a great deal of attention in nanome-
dicine over the past decade. Their unique properties allow
Table 2 24IhC50 values for topo II poisons IONs nanoformulations


































Notes: Cells exposed to different concentrations of Dox or Elli-loaded surface-
coated IONs were assayed for viability by XTT assay at 24 hrs and 24hIC50 values
were calculated using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla,
CA, USA). The applied concentrations were normalized using the intrinsic fluores-
cence of Dox and Elli. Surface-coated IONs without bound cytotoxic agents were
normalized to the total iron using AAS. 24hIC50 values are means of six indepen-
dent experiments (n=6, mean ± standard error).
Abbreviations: Dox, doxorubicin; Elli, ellipticine; IONs, iron oxide nanoparticles;
PVP, polyvinylpyrrolidone; POES, polyoxyethylene stearate; Chit, chitosan; XTT, 2,3-
bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide; AAS, atomic
absorption spectrometry.
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them for applications including magnetic resonance ima-
ging, magnetic fluid hyperthermia or magnetic drug deliv-
ery vehicles.3–6,37 Among other superb intrinsic properties,
a capability for simple surface functionalization makes
IONs exceptional candidates for a tailoring of drug-speci-
fic delivery vehicles. Therefore, in the present study, we
aimed at the synthesis and ultrasound-mediated surface
coating of IONs toward a loading and sustained release
of topo II poisons Dox and Elli.
Bare IONs prepared by oxidizing Fe(OH)2 gel in the
presence of KNO3
24 were surface-coated with three differ-
ent polymers/surfactant (PVP, POES, Chit), known for
their biocompatibility, biodegradability and ability to
enhance the solubility of drugs.38,39 Coating agents were
deposited through ultrasound that generates acoustic cavi-
tation, which impacts the solid surface of IONs and causes
mechanical collisions40 observable in SEM micrographs in
Figures 1B and 2B. Despite the collisions could have
deleterious effects on nanomaterials, we found that upon
coating, IONs exhibited good colloidal stability, which can
be attributed to an effective repulsive force caused by
organic coatings.41
Apart from the sonochemical deposition of organic coat-
ings, we evaluated the efficiency of ultrasound-mediated
tethering of Dox and Elli and compared this approach
with the loading of topo II poisons through a continuous
agitation. Indeed, we found that a second-step of sonochem-
ical modification resulted in pronouncedly higher LEs for
Figure 4 Evaluation of potential synergic effects of IONs to Dox and Elli cytotoxicity. (A) Isobolograms demonstrating synergistic/antagonistic effects of selected surface-
coated IONs and Dox/Elli within all tested cell lines. (B) Total iron accumulation in intracellular region of treated cells (6 hrs) analyzed by AAS. The values are expressed as
the mean of three independent replicates (n=3). The vertical bars indicate standard error. (C) Internalization kinetics of Dox@IONs-POES and Elli@IONs-PVP analyzed
using CLSM in all tested cell lines during the first 6 hrs of treatment. Scale bar, 15 µm.
Abbreviations: Dox, doxorubicin; Elli, ellipticine; IONs, iron oxide nanoparticles; AAS, atomic absorption spectroscopy; CLSM, confocal laser scanning microscopy; CI,
combination index.
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Dox and Elli. Although this process was accompanied by
additional collisions of IONs and formation of small frag-
ments, resulting nanoformulations of Dox and Elli exhibited
relatively narrow size distribution and fast response to EMF.
Despite the specific mechanism responsible for enhanced
LEs due to ultrasonication are not known, we anticipate that
surface collisions and incurred debris increased the binding
surface for loading of topo II poisons.42 Since bare IONs
did not reach comparable LEs for both topo II poisons,
surface coatings are obviously crucial for this process.
Noteworthy, both IONs-POES and IONS-PVP were capable
to load sufficient amounts of Dox and Elli, which is in good
agreement with previously published studies.38,43
Interestingly, despite IONs-Chit exhibited the highest
amount of surface organic matter, considerably lower LEs
were achieved for both topo II poisons. Moreover, due to
unfavorable cumulative release profiles, IONs-Chit was
excluded from further experiments.
Despite we did not investigated the chemical interactions
responsible for efficient drug loadings to IONs-PVP and
IONs-POES, based on the available literature, we anticipate
that hydrazine moiety of PVP forms hydrazone bonds with
ketonic groups of Dox.44 Since Elli is poorly water-soluble
compound, we hypothesize that presence of both, PVP or
POES increases its solubility and promotes the biding to sur-
face-coated IONs.45 However, to prove this, additional inves-
tigations might be done. Importantly, we found that
Dox@IONs-POES and Elli@IONs-PVP exhibited strong
Figure 5 (A) Representative micrographs of wound-healing assay showing the marked effect of Dox/Elli-tethered surface-modified IONs on a migration of tested cell lines.
Representative pictures demonstrate the artificial gaps at the experimental start-point (0 hrs) and migration of cells after 24 hrs cultivation. Yellow lines indicate the
approximate borders of the initial gap. Scale bar, 400 µm. (B) Quantitation of relative free areas from wound-healing assay. The values are expressed as the mean of three
independent replicates (n=3). Vertical bars indicate + and −errors. *P<0.05, **P<0.01 related to the initial gap area. (C) SCGE of cells following exposure to Dox@IONs-
POES and Elli@IONs-PVP. PBS (pH 7.4) and 60 µM H2O2 were employed as negative and positive controls. Scale bar, 100 µm. (D) Quantitation of index of damage upon 12
hrs exposure. The values are expressed as the mean of three independent replicates (n=3). Vertical bars indicate + and −errors. (E) Representative immunoblots of whole-
cell lysate of MDA-MB-231 cells. β-Actin and GAPDH served as loading controls.
Abbreviations: Dox, doxorubicin; Elli, ellipticine; IONs, iron oxide nanoparticles; SCGE, single-cell gel electrophoresis; PBS, phosphate-buffered saline; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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pH-responsive drug release, which may facilitate burst in
endosomes or near the acidic tumor microenvironment.46
In our in vitro experiments, we found some cell type-
dependent differences affecting surface-coated IONs uptake
and subsequent cytotoxicity. In all assays, we found thatmalig-
nant rapidly proliferating MDA-MB-231 cells are more sus-
ceptible to topo II poisons tethered IONs compared to non-
malignant HBL-100 and HEK-293. A plausible explanation is
that cancer cells generally elaborate mechanisms to enhance
endocytosis andmacropinocytosis,47,48 which are known to be
responsible for IONs internalization.49 Additionally, cancer
cells are characterized by a higher membrane fluidity
compared to non-malignant cells.50,51 This fact was supported
by a markedly enhanced accumulation of intracellular iron,
particularly for sonicated IONs consisting of a population of
smaller particles resulting from sonochemistry-triggered colli-
sions of IONs cores (Figure 4B).Upon internalization, surface-
coated IONs nanoformulations retained the known cytotoxic
effects caused by topo II poisons as evidenced by an array of
analyses including analysis of migration, proliferation and of
quantitation of DNA fragmentation.20 Moreover, decrease in
expression of executioner procaspase-3 together with a slight
enhancement of expression of p53 indicates an activation of
apoptotic pathways.52
Figure 6 Examination of in vitro biocompatibility of Dox@IONs-POES and Elli@IONs-PVP. (A) Hemolysis of Dox@IONs-POES and Elli@IONs-PVP assayed on human
RBCs. PBS (pH 7.4) and 0.1% Triton X-100 were utilized as negative and positive controls, respectively. Amount of tested IONs-POES and IONs-PVP without tethered Dox
and Elli is adequate to the highest amount of IONs in Dox@IONs-POES and Elli@IONs-PVP treatments. Upper images depict representative photographs of tested
samples. The values are expressed as the mean of three independent replicates (n=3). Vertical bars indicate + and −errors. *P<0.05, **P<0.01 related to the IONs-POES and
IONs-PVP without tethered topo II poisons. (B) Protein corona patterns obtained after 30 mins incubation of annotated formulations with human plasma followed by
extensive washing, elution, and loading onto 12% SDS-PAGE. As a control, human plasma (1,000× diluted) was loaded to the first lane. Figures on the right side show protein
coronas quantified by densitometric analysis. (C) Immunoblot of C3b binding from human serum from male AB clotted whole blood.
Abbreviations: Dox, doxorubicin; Elli, ellipticine; IONs, iron oxide nanoparticles; RBCs, red blood cells.
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Generally, polymeric/surfactant surface coating pro-
duces biocompatible hybrid materials.53 Remarkably, the
biocompatibility analyses revealed that topo II tethered
surface-coated IONs are pronouncedly hemocompatible
and inert against the formation of protein corona (surface
adsorption of plasma proteins). These properties have
extraordinary importance for further translation of testing
to preclinical in vivo models. We are eager to continue
with this plan in future studies.
Conclusion
In summary, we have demonstrated that surface of bare IONs
can be simply functionalized through an ultrasound-mediated
deposition of organic compounds (PVP, POES or Chit) and
subsequent tethering of topo II poisons (Dox and Elli). Despite
two-step sonochemical modification pipeline causes surface
collisions, surface-coated IONs are capable to bind significant
amounts of Dox and Elli, and to enable for their sustained
release kinetics in slightly acidic pH, mimicking tumor
hypoxia or endosomes. Additionally, surface-coated IONs
exhibited synergistic or additive effects to the cytotoxicity of
topo II poisons in malignant MDA-MB-231 cells, while
slightly antagonistic effects in non-malignant HBL-100 and
HEK-293 cells. Furthermore, due to surface coatings, IONs
nanoformulations exhibited good biocompatibility in vitro.
These findings could support the development of biocompati-
ble delivery systems for topo II poisons to enhance their
therapeutic efficiency.
Acknowledgment
Financial support from the Czech Health Research Council
(AZV project No. 15-28334A), AF-IGA-IP-2018/007 and
CEITEC 2020 (LQ1601) with financial support from the
Ministry of Education, Youth and Sports of the Czech
Republic under the National Sustainability Programme II
is gratefully acknowledged. We thank Milica Gagic for
performing organic element analyses and all co-authors
for their contribution.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-
based medicines: a review of FDA-approved materials and clinical
trials to date. Pharm Res. 2016;33(10):2373–2387. doi:10.1007/
s11095-016-1958-5
2. Skorjanc T, Benyettou F, Olsen JC, Trabolsi A. Design of organic
macrocycle-modified iron oxide nanoparticles for drug delivery.
Chem Eur J. 2017;23(35):8333–8347. doi:10.1002/chem.201605246
3. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles
as a drug delivery vehicle for MRI monitored magnetic targeting
of brain tumors. Biomaterials. 2008;29(4):487–496. doi:10.1016/j.
biomaterials.2007.08.050
4. Zhao Z, Zhou Z, Bao J, et al. Octapod iron oxide nanoparticles as
high-performance T(2) contrast agents for magnetic resonance ima-
ging. Nat Commun. 2013;4:2266. doi:10.1038/ncomms3266
5. Eguchi H, Umemura M, Kurotani R, et al. A magnetic anti-cancer
compound for magnet-guided delivery and magnetic resonance ima-
ging. Sci Rep. 2015;5:14. doi:10.1038/srep09194
6. Wahajuddin AS. Superparamagnetic iron oxide nanoparticles: mag-
netic nanoplatforms as drug carriers. Int J Nanomed. 2012;7:3445–
3471. doi:10.2147/IJN.S30320
7. Quan QM, Xie J, Gao HK, et al. HSA coated iron oxide nanoparticles as
drug delivery vehicles for cancer therapy.Mol Pharm. 2011;8(5):1669–
1676. doi:10.1021/mp200006f
8. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and
challenges towards targeted delivery of cancer therapeutics. Nat
Commun. 2018;9:12. doi:10.1038/s41467-018-03705-y
9. Xie J, Lee S, ChenXY.Nanoparticle-based theranostic agents.AdvDrug
Deliv Rev. 2010;62(11):1064–1079. doi:10.1016/j.addr.2010.07.009
10. Ulbrich K, Hola K, Subr V, Bakandritsos A, Tucek J, Zboril R.
Targeted drug delivery with polymers and magnetic nanoparticles:
covalent and noncovalent approaches, release control, and clinical
studies.Chem Rev. 2016;116(9):5338–5431. doi:10.1021/acs.chemrev.
5b00589
11. Yang XQ, Grailer JJ, Rowland IJ, et al. Multifunctional SPIO/DOX-
loaded wormlike polymer vesicles for cancer therapy andMR imaging.
Biomaterials. 2010;31(34):9065–9073. doi:10.1016/j.biomaterials.
2010.08.039
12. Unterweger H, Tietze R, Janko C, et al. Development and character-
ization of magnetic iron oxide nanoparticles with a cisplatin-bearing
polymer coating for targeted drug delivery. Int J Nanomed.
2014;9:3659–3676. doi:10.2147/IJN.S63433
13. Hamley IW. Nanotechnology with soft materials. Angew Chem Int
Edit. 2003;42(15):1692–1712. doi:10.1002/anie.200200546
14. Jain TK, Foy SP, Erokwu B, Dimitrijevic S, Flask CA, Labhasetwar
V. Magnetic resonance imaging of multifunctional pluronic stabilized
iron-oxide nanoparticles in tumor-bearing mice. Biomaterials.
2009;30(35):6748–6756. doi:10.1016/j.biomaterials.2009.08.042
15. Khandhar AP, Keselman P, Kemp SJ, et al. Evaluation of PEG-coated
iron oxide nanoparticles as blood pool tracers for preclinical mag-
netic particle imaging. Nanoscale. 2017;9(3):1299–1306. doi:10.10
39/c6nr08468k
16. Kayal S, Ramanujan RV. Doxorubicin loaded PVA coated iron oxide
nanoparticles for targeted drug delivery. Mater Sci Eng C-Mater Biol
Appl. 2010;30(3):484–490. doi:10.1016/j.msec.2010.01.006
17. Mulens-Arias V, Rojas JM, Perez-Yague S, Morales MP, Barber DF.
Polyethylenimine-coated SPIONs trigger macrophage activation
through TLR-4 signaling and ROS production and modulate podosome
dynamics. Biomaterials. 2015;52:494–506. doi:10.1016/j.biomaterials.
2015.02.068
18. Kalfalah FM, Mielke C, Christensen MO, Baechler S, Marko D,
Boege F. Genotoxicity of dietary, environmental and therapeutic
topoisomerase II poisons is uniformly correlated to prolongation of
enzyme DNA residence. Mol Nutr Food Res. 2011;55:S127–S142.
doi:10.1002/mnfr.201000509
19. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy.
Nat Rev Cancer. 2009;9(5):338–350. doi:10.1038/nrc2607
20. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in
therapy-related acute promyelocytic leukemia. N Engl J Med.
2005;352(15):1529–1538. doi:10.1056/NEJMoa042715
Michalkova et al Dovepress
submit your manuscript | www.dovepress.com
DovePress





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
21. Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase II beta-mediated
DNA double-strand breaks: implications in doxorubicin cardiotoxi-
city and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839–
8846. doi:10.1158/0008-5472.CAN-07-1649
22. Yuan Y, Wang WN, Wang BL, Zhu HY, Zhang BH, Feng MQ.
Delivery of hydrophilic drug doxorubicin hydrochloride-targeted
liver using apoAI as carrier. J Drug Target. 2013;21(4):367–374.
doi:10.3109/1061186X.2012.757769
23. Kizek R, Adam V, Hrabeta J, et al. Anthracyclines and ellipticines as
DNA-damaging anticancer drugs: recent advances. Pharmacol Ther.
2012;133(1):26–39. doi:10.1016/j.pharmthera.2011.07.006
24. Sugimoto T, Matijevic E. Formation of uniform spherical magnetite
particles by crystallization from ferrous hydroxide gels. J Colloid
Interface Sci. 1980;74(1):227–243. doi:10.1016/0021-9797(80)90187-3
25. Kumar SA, Peter YA, Nadeau JL. Facile biosynthesis, separation and
conjugation of gold nanoparticles to doxorubicin. Nanotechnology.
2008;19:49. doi:10.1088/0957-4484/19/49/495101
26. Chou TC. Theoretical basis, experimental design, and computerized
simulation of synergism and antagonism in drug combination studies.
Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.10
27. Sodipo BK, Aziz AA. Non-seeded synthesis and characterization of
superparamagnetic iron oxide nanoparticles incorporated into silica
nanoparticles via ultrasound. Ultrason Sonochem. 2015;23:354–359.
doi:10.1016/j.ultsonch.2014.09.011
28. Wang Y, Tu S, Pinchuk AN, Xiong MP. Active drug encapsulation and
release kinetics from hydrogel-in-liposome nanoparticles. J Colloid
Interface Sci. 2013;406:247–255. doi:10.1016/j.jcis.2013.05.081
29. Martinez-Torres AC, Zarate-Trivino DG, Lorenzo-Anota HY, Avila-
Avila A, Rodriguez-Abrego C, Rodriguez-Padilla C. Chitosan gold
nanoparticles induce cell death in HeLa and MCF-7 cells through
reactive oxygen species production. Int J Nanomed. 2018;13:3235–
3250. doi:10.2147/IJN.S165289
30. Mai Y, Yu JJ, Bartholdy B, et al. An oxidative stress-based mechan-
ism of doxorubicin cytotoxicity suggests new therapeutic strategies in
ABC-DLBCL. Blood. 2016;128(24):2797–2807. doi:10.1182/blood-
2016-03-705814
31. Savorani C, Manfe V, Biskup E, Gniadecki R. Ellipticine induces
apoptosis in T-cell lymphoma via oxidative DNA damage. Leuk
Lymphoma. 2015;56(3):739–747. doi:10.3109/10428194.2014.929673
32. Gonzalez-Moragas L, Yu SM, Benseny-Cases N, Sturzenbaum S,
Roig A, Laromaine A. Toxicogenomics of iron oxide nanoparticles
in the nematode C-elegans. Nanotoxicology. 2017;11(5):647–657.
doi:10.1080/17435390.2017.1342011
33. Dobrovoiskaia MA, Clogston JD, Neun BW, Hall JB, Patri AK,
McNeil SE. Method for analysis of nanoparticle hemolytic properties
in vitro. Nano Lett. 2008;8(8):2180–2187. doi:10.1021/nl0805615
34. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a
key system for immune surveillance and homeostasis. Nat Immunol.
2010;11(9):785–797. doi:10.1038/ni.1923
35. Chen FF, Wang GK, Griffin JI, et al. Complement proteins bind to
nanoparticle protein corona and undergo dynamic exchange in vivo.
Nat Nanotechnol. 2017;12(4):387–393. doi:10.1038/nnano.2016.269
36. Nguyen VH, Lee BJ. Protein corona: a new approach for nanomedi-
cine design. Int J Nanomed. 2017;12:3137–3151. doi:10.2147/IJN.
S129300
37. Poller JM, Zaloga J, Schreiber E, et al. Selection of potential iron
oxide nanoparticles for breast cancer treatment based on in vitro
cytotoxicity and cellular uptake. Int J Nanomed. 2017;12:3207–
3220. doi:10.2147/IJN.S132369
38. Buchtelova H, Strmiska V, Dostalova S, et al. pH-responsive hybrid
organic-inorganic ruthenium nanoparticles for controlled release of
doxorubicin. Part Syst Charact. 2017;34(11):9. doi:10.1002/
ppsc.201700289
39. Lo YI. Relationships between the hydrophilic-lipophilic balance
values of pharmaceutical excipients and their multidrug resistance
modulating effect in Caco-2 cells and rat intestines. J Control
Release. 2003;90(1):37–48.
40. Shekhar A, Nomura KI, Kalia RK, Nakano A, Vashishta P.
Nanobubble collapse on a silica surface in water: billion-atom reac-
tive molecular dynamics simulations. Phys Rev Lett. 2013;111(18):5.
doi:10.1103/PhysRevLett.111.184503
41. Kamiya H, Iijima M. Surface modification and characterization for
dispersion stability of inorganic nanometer-scaled particles in liquid
media. Sci Technol Adv Mater. 2010;11(4):7. doi:10.1088/1468-6996/
11/4/044304
42. Bui TQ, Ngo HTM, Tran HT. Surface-protective assistance of ultra-
sound in synthesis of superparamagnetic magnetite nanoparticles and
in preparation of mono-core magnetite-silica nanocomposites. J Sci.
2018;3(3):323–330.
43. Ramalingam V, Varunkumar K, Ravikumar V, Rajaram R. Target
delivery of doxorubicin tethered with PVP stabilized gold nanoparti-
cles for effective treatment of lung cancer. Sci Rep. 2018;8:12.
doi:10.1038/s41598-018-22172-5
44. Lee H, Lee K, Kim IK, Park TG. Synthesis, characterization, and in
vivo diagnostic applications of hyaluronic acid immobilized gold
nanoprobes. Biomaterials. 2008;29(35):4709–4718. doi:10.1016/j.
biomaterials.2008.08.038
45. Rahman A, Cradock JC, Davignon JP. Dissolution and absorption of
the antineoplastic agent ellipticine. J Pharm Sci. 1978;67(5):611–
614. doi:10.1002/jps.2600670509
46. Chen BL, Dai WB, He B, et al. Current multistage drug delivery
systems based on the tumor microenvironment. Theranostics. 2017;7
(3):538–558. doi:10.7150/thno.16684
47. Recouvreux MV, Commisso C. Macropinocytosis: a metabolic adap-
tation to nutrient stress in cancer. Front Endocrinol. 2017;8:7.
doi:10.3389/fendo.2017.00261
48. Schmid SL. Reciprocal regulation of signaling and endocytosis:
implications for the evolving cancer cell. J Cell Biol. 2017;216
(9):2623–2632. doi:10.1083/jcb.201705017
49. Yameen B, Choi WI, Vilos C, Swami A, Shi JJ, Farokhzad OC. Insight
into nanoparticle cellular uptake and intracellular targeting. J Control
Release. 2014;190:485–499. doi:10.1016/j.jconrel.2014.06.038
50. Peetla C, Vijayaraghavalu S, Labhasetwar V. Biophysics of cell
membrane lipids in cancer drug resistance: implications for drug
transport and drug delivery with nanoparticles. Adv Drug Deliv Rev.
2013;65(13–14):1686–1698. doi:10.1016/j.addr.2013.09.004
51. Sok M, Sentjurc M, Schara M, Stare J, Rott T. Cell membrane fluidity
and prognosis of lung cancer. Ann Thorac Surg. 2002;73(5):1567–
1571. doi:10.1016/s0003-4975(02)03458-6
52. Geng QQ, Dong DF, Chen NZ, et al. Induction of p53 expression and
apoptosis by a recombinant dual-target MDM2/MDMX inhibitory
protein in wild-type p53 breast cancer cells. Int J Oncol. 2013;43
(6):1935–1942. doi:10.3892/ijo.2013.2138
53. Zhang XY, Zeng GJ, Tian JW, et al. PEGylation of carbon nanotubes
via mussel inspired chemistry: preparation, characterization and bio-
compatibility evaluation. Appl Surf Sci. 2015;351:425–432.
doi:10.1016/j.apsusc.2015.05.160
Dovepress Michalkova et al







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine Dovepress
Publish your work in this journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology in
diagnostics, therapeutics, and drug delivery systems throughout the
biomedical field. This journal is indexed on PubMed Central,
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,
Journal Citation Reports/Science Edition, EMBase, Scopus and the
Elsevier Bibliographic databases. The manuscript management system
is completely online and includes a very quick and fair peer-review
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/international-journal-of-nanomedicine-journal
Michalkova et al Dovepress
submit your manuscript | www.dovepress.com
DovePress





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
